Estados Unidos · Bolsa y Finanzas · Morningstar

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

Publicado por Morningstar · Estados Unidos hace 16 h

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss In the MEERKAT and SANDCAT studies, vamikibart…

Leer el artículo completo en Morningstar Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.morningstar.com)

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

También te puede interesar

Microsoft’s Satya Nadella says AI models need an ‘emergency brake’

Satya Nadella says a company's relationship with AI should have trust issues

Pemex Needs Nearly $110 Billion to Hit Mexico's Output Targets

Microsoft's Nadella says AI needs an ‘emergency brake’ that humans control

SA Asks: Is now the time to buy quantum stocks? If so, which ones?

Ship captains and crews transiting the Strait of Hormuz make so much danger pay that they’re ‘almost being viewed as mercenaries’

Genentech Presents New Phase III One-Year Data for Vamikibart in Uveitic Macular Edema (UME), a Serious Cause of Vision Loss

Compartir

También te puede interesar

Microsoft’s Satya Nadella says AI models need an ‘emergency brake’

Satya Nadella says a company's relationship with AI should have trust issues

Pemex Needs Nearly $110 Billion to Hit Mexico's Output Targets

Microsoft's Nadella says AI needs an ‘emergency brake’ that humans control

SA Asks: Is now the time to buy quantum stocks? If so, which ones?

Ship captains and crews transiting the Strait of Hormuz make so much danger pay that they’re ‘almost being viewed as mercenaries’